Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
Portfolio Pulse from AJ Fabino
The FDA has approved updated COVID-19 vaccines by Moderna and Pfizer-BioNTech to counter current viral strains, including the omicron variant. The vaccines are expected to be ready by fall. Novavax, another company in the race to update its COVID-19 vaccine, saw its shares fall almost 13% after the approval of Pfizer's and Moderna's vaccines.
September 11, 2023 | 8:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech's updated COVID-19 vaccine, developed in partnership with Pfizer, has been approved by the FDA, which could positively impact its stock.
The FDA approval of Pfizer-BioNTech's updated COVID-19 vaccine is a positive development for the companies and could lead to an increase in their stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna's updated COVID-19 vaccine has been approved by the FDA, which could boost its stock.
The FDA approval of Moderna's updated COVID-19 vaccine is a positive development for the company and could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's updated COVID-19 vaccine, developed in partnership with BioNTech, has been approved by the FDA, which could positively impact its stock.
The FDA approval of Pfizer-BioNTech's updated COVID-19 vaccine is a positive development for the companies and could lead to an increase in their stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Novavax's shares fell almost 13% after the FDA approved Pfizer's and Moderna's updated COVID-19 vaccines. The company's vaccine is still awaiting FDA approval.
The FDA approval of Pfizer's and Moderna's updated COVID-19 vaccines led to a drop in Novavax's stock price as the company's vaccine is still awaiting FDA approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100